Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Sphingosylphosphorylchloline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.77 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.67 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.67 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.67 |
| ▸ | TSPO | P30536 | 1/20 | 0.67 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.67 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | P2RY10 | O00398 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GMNN | O75496 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | CETP | P11597 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sphingosylphosphorylchloline SCHEMBL196291 | 1.00 | MEN1 (0.77) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosylphosphorylchloline SCHEMBL196365 | 0.99 | MEN1 (0.78) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosylphosphorylchloline SCHEMBL12513601 | 0.99 | MEN1 (0.78) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| SCHEMBL17696724 | 0.89 | S1PR1 (0.77) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| SCHEMBL17775054 | 0.87 | S1PR1 (0.62) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosylphosphorylchloline SCHEMBL195431 | 0.87 | S1PR1 (1.00) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosylphosphorylchloline SCHEMBL19928025 | 0.87 | S1PR1 (1.00) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| SCHEMBL31427625 | 0.87 | S1PR1 (1.00) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| SCHEMBL29602895 | 0.86 | S1PR1 (0.73) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosine SCHEMBL195430 | 0.85 | MEN1 (0.67) | MEN1KMT2AS1PR1S1PR4S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104650225-B | Composition and method for binding sphingosine alcohol -1- phosphoric acid | 勒帕斯公司 | 2019-10-01 | — | — | CN | disclosed |
| US-9274129-B2 | Methods and reagents for detecting bioactive lipids | LPATH, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9217749-B2 | Immune-derived moieties reactive against lysophosphatidic acid | LPATH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150203570-A1 | PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO SPHINGOSINE-1-PHOSPHATE | APOLLO ENDOSURGERY, INC. | 2015-07-23 | — | — | US | disclosed |
| CN-104650225-A | COMPOSITIONS AND METHODS FOR BINDING SPHINGOSINE-1-PHOSPHATE | LPATH INC | 2015-05-27 | — | — | CN | disclosed |
| CN-101679506-B | Compositions and methods for binding sphingosine-1-phosphate | LPATH INC | 2015-02-25 | — | — | CN | disclosed |
| US-20150031055-A1 | NOVEL BIOACTIVE LIPID DERIVATIVES, AND METHODS OF MAKING AND USING THE SAME | LPATH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-8871202-B2 | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate | LPATH, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2087002-B1 | COMPOSITIONS AND METHODS FOR BINDING SPHINGOSINE-1-PHOSPHATE | LPATH INC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140186339-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND CONDITIONS | LPATH, INC. | 2014-07-03 | — | — | US | disclosed |
| US-20090130100-A1 | METHODS OF USING HUMANIZED ANTIBODIES AND COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE | APOLLO ENDOSURGERY, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090130099-A1 | HUMANIZED ANTIBODIES AND COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE | INNOVATUS LIFE SCIENCES LENDING FUND I, LP | 2009-05-21 | — | — | US | disclosed |
| US-20090074789-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND CONDITIONS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP | 2009-03-19 | — | — | US | disclosed |
| US-20090010922-A1 | COMPOSITIONS AND METHODS FOR BINDING SPHINGOSINE-1-PHOSPHATE | INNOVATUS LIFE SCIENCES LENDING FUND I, LP | 2009-01-08 | — | — | US | disclosed |
| WO-2008070344-A9 | COMPOSITIONS AND METHODS FOR BINDING SPHINGOSINE-1-PHOSPHATE | LPATH THERAPEUTICS INC (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080145360-A1 | Lysolipid specific immunoglobulin for use in diagnosis, prevention and treatment of blood and cell proliferative disorders | INNOVATUS LIFE SCIENCES LENDING FUND I, LP | 2008-06-19 | — | — | US | disclosed |
| WO-2008070344-A2 | COMPOSITIONS AND METHODS FOR BINDING SPHINGOSINE-1-PHOSPHATE | LPATH, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080138334-A1 | Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same | SABBADINI ROGER A | 2008-06-12 | — | — | US | disclosed |
| WO-2008055072-A2 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND CONDITIONS | LPATH, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20080090303-A1 | Methods and Reagents for Detecting Bioactive Lipids | APOLLO ENDOSURGERY, INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145360-A1 | Lysolipid specific immunoglobulin for use in diagnosis, prevention and treatment of blood and cell proliferative disorders | CD47, SGMS1, ALG1 | MEN1 1652/4885KMT2A 970/4885S1PR1 9/4885 |
| US-20080138334-A1 | Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same | CD47, ALG1, SGMS1 | MEN1 1608/4885KMT2A 1455/4885S1PR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.